▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent Articles by Max Macaluso

Oct 16, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

The Bear and Bull Cases for Amarin

Why are some investors bearish and others bullish on this controversial biotech stock?

Oct 11, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Down 20%: Ariad Pharmaceuticals' Second Dose of Bad News

Shares of Ariad plunged 70% earlier this week -- why did the shares drop another 20% today?

Oct 6, 2013 by Max Macaluso and Dave Williamson

The Government Shutdown Won't Stop This FDA Meeting

Amarin's triglyceride-lowering drug Vascepa competes with GlaxoSmithKline's Lovaza and may also go head-to-head with AstraZeneca's Epanova next year, but Vascepa's FDA advisory committee meeting in October is far more important to investors.

Oct 6, 2013 by Max Macaluso and Dave Williamson

Can This Obesity-Drug Maker Beat Arena and VIVUS in Europe?

Arena and VIVUS have been failed to get their drugs on the market in the EU, but can Orexigen jump over the regulatory hurdle and beat them to market?

Oct 3, 2013 by Max Macaluso

Omeros Corporation's Eye-Popping Surge

Why are shares of biotech company Omeros jumping today?

Sep 30, 2013 by Max Macaluso and Dave Williamson

2 Stocks to Watch as Obamacare Exchanges Roll Out

Two stocks soaring from Obamacare.

Sep 29, 2013 by Max Macaluso and Dave Williamson

Is Pfizer's Oncology Division Poised to Grow?

A deep dive into Pfizer's oncology portfolio and pipeline.

Sep 27, 2013 by Max Macaluso and Dave Williamson

Time to Panic About Merck's Patent Expirations?

A look at which products Merck will lose patent protection on in the coming years.

Sep 26, 2013 by Max Macaluso

AbbVie's 3 Biggest Opportunities

What are the three opportunities that AbbVie investors need to watch? (Companies discussed in this video are ABBV and GILD.)

Sep 26, 2013 by Max Macaluso

3 Dividends Investors Love

Sanofi, Bristol-Myers Squibb, and Teva are three health-care stocks that The Motley Fool CAPS players rate highly, but are they all well positioned?

Sep 26, 2013 by Max Macaluso

3 Reasons Behind Rite Aid's Incredible Run

Retail pharmacies like CVS and Walgreen have performed well so far this year, but why is Rite Aid up a surprising 250%?

Sep 26, 2013 by Max Macaluso and Dave Williamson

Should Merck Copy Pfizer and Join the "Spinoff Club"?

Pfizer spun out its animal health unit, Zoetis, in 2013. Should Merck do the same?

Sep 26, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

What Was Behind Pacific Biosciences' 70% Pop?

The details behind Roche's deal with Pacific Biosciences of California.

Sep 25, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

The Details Behind MAKO Surgical's 80% Pop

The acquisition that boosted MAKO's share price today.

Sep 25, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Market Checkup: Sept. 25

Today's health-care headlines.

Sep 25, 2013 by Max Macaluso and Dave Williamson

3 Reasons to Sell Bristol-Myers Squibb

Are there any reasons to sell one of the best performing pharmaceutical stocks of the year?

Sep 25, 2013 by Max Macaluso

Stryker's Shocking Move for Mako Surgical

Stryker's $1.65 billion offer to buy struggling robotic surgery company Mako takes the market by surprise.

Sep 24, 2013 by Max Macaluso and Dave Williamson

3 Catalysts Bristol-Myers Squibb Investors Need to Watch

What are the key events that Bristol-Myers Squibb investors need to watch in the coming months?

Sep 24, 2013 by Max Macaluso, Dave Williamson, and Alison Southwick

Can Merck Recover From This FDA Rejection?

Merck's latest setback comes from the Food and Drug Administration's rejection of sugammadex.

Sep 23, 2013 by Max Macaluso and Dave Williamson

The Best Big Pharma Dividend Stocks?

Tune in as our analysts debate whether Johnson & Johnson, Merck, AstraZeneca, or Bristol-Myers Squibb is the best big pharma dividend stock today.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services